BRIEF-Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities

Reuters
13 Jan
BRIEF-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Key Anticipated 2025 Milestones and Priorities

Jan 13 (Reuters) - Denali Therapeutics Inc DNLI.O:

  • DENALI THERAPEUTICS INC: PREPARING FOR COMMERCIAL LAUNCH OF TIVIDENOFUSP ALFA FOR HUNTER SYNDROME IN LATE 2025 OR EARLY 2026

  • DENALI THERAPEUTICS INC: ANTICIPATES ITS CASH RUNWAY WILL EXTEND INTO 2028

Source text: ID:nGNX2kZ48Y

Further company coverage: DNLI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10